IDEAYA Biosciences, Inc. NASDAQ:IDYA

Founder-led company

IDEAYA Biosciences stock price today

$23.58
-1.58
-6.28%
Financial Health
0
1
2
3
4
5
6
7
8
9

IDEAYA Biosciences stock price monthly change

-37.10%
month

IDEAYA Biosciences stock price quarterly change

-37.10%
quarter

IDEAYA Biosciences stock price yearly change

-28.81%
year

IDEAYA Biosciences key metrics

Market Cap
2.18B
Enterprise value
499.32M
P/E
-8.79
EV/Sales
9.80
EV/EBITDA
-9.11
Price/Sales
11.08
Price/Book
1.61
PEG ratio
12.39
EPS
-2.01
Revenue
N/A
EBITDA
-158.14M
Income
-128.89M
Revenue Q/Q
-100%
Revenue Y/Y
-67.32%
Profit margin
-119.27%
Oper. margin
-122.72%
Gross margin
0%
EBIT margin
-122.72%
EBITDA margin
N/A
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

IDEAYA Biosciences stock price history

IDEAYA Biosciences stock forecast

IDEAYA Biosciences financial statements

Average Price Target
Last Year

$54.11

Potential upside: 129.47%

Based on estimate of 8 analysts
  • Analysts Price target

  • Financials & Ratios estimates

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Profit margin
Jun 2023 3.54M -27.92M -787.98%
Sep 2023 8.03M -27.44M -341.38%
Dec 2023 3.92M -33.95M -865.54%
Mar 2024 0 -39.57M
IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Debt to assets
Jun 2023 527557000 527.55M 100%
Sep 2023 532942000 24.89M 4.67%
Dec 2023 649316000 28.22M 4.35%
Mar 2024 961527000 26.21M 2.73%
IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Cash Flow
Jun 2023 -33.46M -121.38M 191.06M
Sep 2023 -30.17M 51.34M 27.83M
Dec 2023 -23.74M -111.94M 140.89M
Mar 2024 -43.81M -353.97M 349.11M

IDEAYA Biosciences alternative data

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Employee count
Sep 2023 116
Oct 2023 116
Nov 2023 116
Dec 2023 122
Jan 2024 122
Feb 2024 122
Mar 2024 124
Apr 2024 124
May 2024 124
Jun 2024 124
Jul 2024 124

IDEAYA Biosciences other data

35.22% -64.78%
of IDYA is owned by hedge funds
14.59M -31.47M
shares is hold by hedge funds

IDEAYA Biosciences, Inc. (NASDAQ:IDYA): Insider trades (number of shares)
Period Buy Sel
Jul 2023 0 9485
Aug 2023 0 17500
Sep 2023 0 6837
Nov 2023 0 5163
Dec 2023 0 87000
Jan 2024 0 79000
Feb 2024 0 102000
May 2024 0 203500
Transaction Date Insider Security Shares Price per share Total value Source
Option
THRONE JASON officer: Chief Le.. Common Stock 47,060 $7.01 $329,891
Option
THRONE JASON officer: Chief Le.. Stock Option (Right to Buy) 6,424 $13.34 $85,696
Option
THRONE JASON officer: Chief Le.. Common Stock 6,424 $13.34 $85,696
Option
THRONE JASON officer: Chief Le.. Stock Option (Right to Buy) 47,060 $7.01 $329,891
Option
WHITE MICHAEL ANTHONY officer: Chief Scientific Officer
Stock Option (right to buy) 28,500 $12.86 $366,510
Option
WHITE MICHAEL ANTHONY officer: Chief Scientific Officer
Common Stock 28,500 $12.86 $366,510
Sale
WHITE MICHAEL ANTHONY officer: Chief Scientific Officer
Common Stock 27,649 $36.23 $1,001,585
Sale
WHITE MICHAEL ANTHONY officer: Chief Scientific Officer
Common Stock 851 $36.78 $31,296
Option
HATA YUJIRO S director, officer.. Common Stock 34,433 $4.31 $148,406
Sale
HATA YUJIRO S director, officer.. Common Stock 30,084 $41.73 $1,255,496
Patent
Application
Filling date: 25 Sep 2018 Issue date: 21 Jul 2022
Application
Filling date: 9 Dec 2019 Issue date: 7 Apr 2022
Application
Filling date: 29 Jan 2020 Issue date: 31 Mar 2022
Application
Filling date: 30 Jan 2020 Issue date: 16 Dec 2021
Application
Filling date: 17 Jun 2019 Issue date: 2 Dec 2021
Grant
Filling date: 12 Feb 2021 Issue date: 28 Sep 2021
Application
Filling date: 5 Jun 2019 Issue date: 19 Aug 2021
Grant
Filling date: 12 Feb 2021 Issue date: 10 Aug 2021
Grant
Filling date: 12 Feb 2021 Issue date: 29 Jun 2021
Application
Filling date: 18 Jul 2018 Issue date: 22 Apr 2021
Sunday, 29 December 2024
prnewswire.com
Friday, 27 December 2024
prnewswire.com
Tuesday, 17 December 2024
prnewswire.com
Monday, 16 December 2024
prnewswire.com
Wednesday, 11 December 2024
prnewswire.com
Tuesday, 10 December 2024
prnewswire.com
Monday, 9 December 2024
prnewswire.com
Friday, 6 December 2024
prnewswire.com
Wednesday, 4 December 2024
seekingalpha.com
Monday, 2 December 2024
prnewswire.com
Friday, 29 November 2024
prnewswire.com
Monday, 18 November 2024
prnewswire.com
Tuesday, 12 November 2024
prnewswire.com
Monday, 11 November 2024
prnewswire.com
businesswire.com
businesswire.com
Thursday, 7 November 2024
zacks.com
Monday, 4 November 2024
prnewswire.com
Friday, 1 November 2024
prnewswire.com
Tuesday, 29 October 2024
zacks.com
Monday, 28 October 2024
prnewswire.com
Friday, 25 October 2024
prnewswire.com
Friday, 4 October 2024
prnewswire.com
Friday, 27 September 2024
prnewswire.com
Monday, 23 September 2024
benzinga.com
prnewswire.com
Sunday, 22 September 2024
prnewswire.com
Friday, 20 September 2024
seekingalpha.com
Friday, 30 August 2024
prnewswire.com
Monday, 26 August 2024
prnewswire.com
  • What's the price of IDEAYA Biosciences stock today?

    One share of IDEAYA Biosciences stock can currently be purchased for approximately $23.58.

  • When is IDEAYA Biosciences's next earnings date?

    Unfortunately, IDEAYA Biosciences's (IDYA) next earnings date is currently unknown.

  • Does IDEAYA Biosciences pay dividends?

    No, IDEAYA Biosciences does not pay dividends.

  • How much money does IDEAYA Biosciences make?

    IDEAYA Biosciences has a market capitalization of 2.18B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 54.08% to 23.39M US dollars.

  • What is IDEAYA Biosciences's stock symbol?

    IDEAYA Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "IDYA".

  • What is IDEAYA Biosciences's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of IDEAYA Biosciences?

    Shares of IDEAYA Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are IDEAYA Biosciences's key executives?

    IDEAYA Biosciences's management team includes the following people:

    • Mr. Yujiro S. Hata Co-Founder, Chief Executive Officer, Pres & Director(age: 51, pay: $711,330)
    • Mr. Paul A. Stone Senior Vice President, Chief Financial Officer & Principal Accounting Officer(age: 61, pay: $508,440)
    • Mr. Jason S. Throne J.D., Esq. Senior Vice President, Gen. Counsel & Company Sec.(age: 53, pay: $425,560)
  • Is IDEAYA Biosciences founder-led company?

    Yes, IDEAYA Biosciences is a company led by its founder Mr. Yujiro S. Hata.

  • How many employees does IDEAYA Biosciences have?

    As Jul 2024, IDEAYA Biosciences employs 124 workers.

  • When IDEAYA Biosciences went public?

    IDEAYA Biosciences, Inc. is publicly traded company for more then 6 years since IPO on 23 May 2019.

  • What is IDEAYA Biosciences's official website?

    The official website for IDEAYA Biosciences is ideayabio.com.

  • Where are IDEAYA Biosciences's headquarters?

    IDEAYA Biosciences is headquartered at 7000 Shoreline Court, South San Francisco, CA.

  • How can i contact IDEAYA Biosciences?

    IDEAYA Biosciences's mailing address is 7000 Shoreline Court, South San Francisco, CA and company can be reached via phone at +65 04436209.

  • What is IDEAYA Biosciences stock forecast & price target?

    Based on 8 Wall Street analysts` predicted price targets for IDEAYA Biosciences in the last 12 months, the avarage price target is $54.11. The average price target represents a 129.47% change from the last price of $23.58.

IDEAYA Biosciences company profile:

IDEAYA Biosciences, Inc.

ideayabio.com
Exchange:

NASDAQ

Full time employees:

124

Industry:

Biotechnology

Sector:

Healthcare

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

7000 Shoreline Court
South San Francisco, CA 94080

CIK: 0001676725
ISIN: US45166A1025
CUSIP: 45166A102